212573-56-3

Basic information

• Product Name: Pyridine, 5-(bromomethyl)-2-phenyl-
• CAS NO: 212573-56-3
• Molecular Formula: C12H10BrN
• Molecular Weight: 248.122
• Mol File: 212573-56-3.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Pyridine, 5-(bromomethyl)-2-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 5-(bromomethyl)-2-phenyl-(212573-56-3)
• EPA Substance Registry System: Pyridine, 5-(bromomethyl)-2-phenyl-(212573-56-3)

Safety Data

• Hazardous Substances Data: 212573-56-3(Hazardous Substances Data)

Upstream product

• 63056-20-2 2-phenyl-5-pyridinecarboxaldehyde 
• 3510-66-5 2-Bromo-5-methylpyridine 
• 24388-23-6 2-phenyl-4,4,5,5-tetramethyl-1,3,2-dioxoborole 
• 18368-64-4 2-chloro-5-methylpyridine 
• 98-80-6 phenylboronic acid 
• 149806-06-4 6-bromonicotinaldehyde 
• 4634-09-7 2-phenyl-5-hydroxymethylpyridine 
• 27012-22-2 5-methyl-2-phenylpyridine 

Downstream Products

• 945267-56-1 C₄₂H₃₉N₃O₃ 
• 1447908-60-2 5-((5-methoxypyridin-3-yl)methyl)-2-phenylpyridine 
• 1447908-61-3 5-((6-phenylpyridin-3-yl)methyl)pyridin-3-ol 
• 1373310-90-7 2-phenyl-5-(pyridin-3-ylmethyl)pyridine 
• 1373310-89-4 2-phenyl-5-(pyridin-4-ylmethyl)pyridine 
• 1373310-92-9 4-((6-phenylpyridin-3-yl)methyl)isoquinoline 
• 1373311-07-9 5-((4-methylpyridin-3-yl)methyl)-2-phenylpyridine 
• 1373310-97-4 5-((6-phenylpyridin-3-yl)methyl)pyrimidine 
• 1373311-09-1 5-((5-methylpyridin-3-yl)methyl)-2-phenylpyridine 
• 1447908-57-7 5-((6-phenylpyridin-3-yl)methyl)nicotinamide 
• 1447908-58-8 5-((5-fluoropyridin-3-yl)methyl)-2-phenylpyridine 
• 934337-57-2 diethyl (2-phenylpyridin-5-yl)methylphosphonate 

Relevant articles and documents

COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF

A compound of formula (I), a preparation method therefor, a pharmaceutical composition containing a derivative thereof, and the therapeutic uses thereof, especially inhibiting PGE2/EP4 signalling transduction and the uses thereof for treating cancer, acute or chronic pain, migraine, osteoarthritis, rheumatoid arthritis, gout, bursitis, ankylosing spondylitis, primary dysmenorrhea, tumour or arteriosclerosis.

END CAPPED NUCLEIC ACID MOLECULES

The disclosure relates to nucleic acids that contain modifications at the 5'-end, 3'-end or 5'-end and 3'-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower imm

Synthesis of facial cyclometalated iridium(iii) complexes triggered by tripodal ligands

The tripodal ligands composed of the 1,3,5-trisubstituted cyclohexyl moiety as a molecular scaffold and 2-phenylpyridyl moieties as a coordination site were designed. The homoleptic cyclometalated fac-Ir(C^N)3 complexes could be obtained by the reaction of IrCl3·nH2O with the designed tripodal ligands. The single crystal X-ray structure determination confirmed the fac configuration and a distorted octahedral geometry with three intramolecular cyclometalated 2-phenylpyridyl ligands surrounding the iridium metal center. Also, the cyclohexyl scaffold was found to serve as a flexible scaffold to induce the fac configuration. The thus-obtained homoleptic cyclometalated fac-Ir(C^N)3 complexes exhibited a broad emission band in the emission spectra at 298 K.